	Substitute Form PTO-1449 (Mod M40)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 16554-002001	Application No. 10/670,122
	<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)				Applicant Salim Yusuf et al.	
					Filing Date September 24, 2003	Group Art Unit 1641

### U.S. Patent Documents


Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
DV	AL	01013459	01/18/89	JP (abstract only)	G01N	33/53	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
↓	AM	01 31052 A1	05/03/01	WIPO	C12Q	1/00	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
	AN							
	AO							
	AP							

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
DV	AQ	Database Internet 'Online! 2003 Cayman Chemical Inc: "519501 11 dehydro thromboxane assay" retrieved from <a href="http://www.caymanchem.com">www.caymanchem.com</a> XP002262581 abstract.
↓	AR	Eikelboom et al., "Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events", Circulation 105:1650-1655, 2002, XP002262579.
↓	AS	Hayashi et al., "Enzyme Immunoassay of Thromboxane B <sub>2</sub> ", Biochimica et Biophysica Acta 750:322-329, 1983, XP009020472.
↓	AT	Reinke et al., "Development of an Enzyme-Linked Immunosorbent Assay of Thromboxane B <sub>2</sub> Using a Monoclonal Antibody", Prostaglandins 37:577-586, 1989, XP009020476.

Examiner Signature 	Date Considered 7/9/04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 1 of 1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16554-002001	Application No. 10/670,122
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Salim Yusuf et al.	
		Filing Date September 24, 2003	Group Art Unit 1641

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
DV	AA	5,240,917	08/31/93	Keimowitz et al.	514	159	X
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
DV	AQ	Eikelboom et al., "Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events", Circulation 105:1650-1655, 2002.
	AR	
	AS	
	AT	

Examiner Signature <i>Don Veri</i>	Date Considered 7/9/04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)